134 related articles for article (PubMed ID: 9172011)
1. Ricin toxin contains three lectin sites which contribute to its in vivo toxicity.
Fu T; Burbage C; Tagge EP; Brothers T; Willingham MC; Frankel AE
Int J Immunopharmacol; 1996 Dec; 18(12):685-92. PubMed ID: 9172011
[TBL] [Abstract][Full Text] [Related]
2. Ricin toxin contains at least three galactose-binding sites located in B chain subdomains 1 alpha, 1 beta, and 2 gamma.
Frankel AE; Burbage C; Fu T; Tagge E; Chandler J; Willingham MC
Biochemistry; 1996 Nov; 35(47):14749-56. PubMed ID: 8942636
[TBL] [Abstract][Full Text] [Related]
3. Double-lectin site ricin B chain mutants expressed in insect cells have residual galactose binding: evidence for more than two lectin sites on the ricin toxin B chain.
Fu T; Burbage C; Tagge E; Chandler J; Willingham M; Frankel A
Bioconjug Chem; 1996; 7(6):651-8. PubMed ID: 8950484
[TBL] [Abstract][Full Text] [Related]
4. IL2 fused to lectin-deficient ricin is toxic to human leukemia cells expressing the IL2 receptor.
Frankel AE; Fu T; Burbage C; Chandler J; Willingham MC; Tagge EP
Leukemia; 1997 Jan; 11(1):22-30. PubMed ID: 9001414
[TBL] [Abstract][Full Text] [Related]
5. Lectin-deficient ricin toxin intoxicates cells bearing the D-mannose receptor.
Frankel AE; Fu T; Burbage C; Tagge E; Harris B; Vesely J; Willingham MC
Carbohydr Res; 1997 May; 300(3):251-8. PubMed ID: 9202409
[TBL] [Abstract][Full Text] [Related]
6. Characterization of single site ricin toxin B chain mutants.
Frankel A; Tagge E; Chandler J; Burbage C; Hancock G; Vesely J; Willingham M
Bioconjug Chem; 1996; 7(1):30-7. PubMed ID: 8741988
[TBL] [Abstract][Full Text] [Related]
7. Double-site ricin B chain mutants retain galactose binding.
Frankel A; Tagge E; Chandler J; Burbage C; Willingham M
Protein Eng; 1996 Apr; 9(4):371-9. PubMed ID: 8738213
[TBL] [Abstract][Full Text] [Related]
8. Strong protection against ricin challenge induced by a novel modified ricin A-chain protein in mouse model.
Zhang T; Yang H; Kang L; Gao S; Xin W; Yao W; Zhuang X; Ji B; Wang J
Hum Vaccin Immunother; 2015; 11(7):1779-87. PubMed ID: 26038805
[TBL] [Abstract][Full Text] [Related]
9. Preproricin expressed in Nicotiana tabacum cells in vitro is fully processed and biologically active.
Tagge EP; Chandler J; Harris B; Czako M; Marton L; Willingham MC; Burbage C; Afrin L; Frankel AE
Protein Expr Purif; 1996 Aug; 8(1):109-18. PubMed ID: 8812841
[TBL] [Abstract][Full Text] [Related]
10. Restoration of lectin activity to a non-glycosylated ricin B chain mutant by the introduction of a novel N-glycosylation site.
Zhan J; de Sousa M; Chaddock JA; Roberts LM; Lord JM
FEBS Lett; 1997 May; 407(3):271-4. PubMed ID: 9175866
[TBL] [Abstract][Full Text] [Related]
11. Recombinant ricin toxin A chain cytotoxicity against carcinoembryonic antigen expressing tumour cells mediated by a bispecific monoclonal antibody and its potentiation by ricin toxin B chain.
Embleton MJ; Charleston A; Robins RA; Pimm MV; Baldwin RW
Br J Cancer; 1991 May; 63(5):670-4. PubMed ID: 2039690
[TBL] [Abstract][Full Text] [Related]
12. Comparison of properties of mistletoe lectin I A-chain and ricin B-chain conjugate with native toxins.
Tonevitsky AG; Toptygin AYu ; Shamshiev AT; Agapov II; Ershova EV; Pfuller U; Pfuller K
FEBS Lett; 1993 Dec; 336(1):100-2. PubMed ID: 8262189
[TBL] [Abstract][Full Text] [Related]
13. The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: assessment of LD50 and MTD of four ricin-based anti-cCLLa immunotoxins (ITs) in Balb/c mice.
Faguet GB; Agee JF
Leuk Lymphoma; 1997 May; 25(5-6):531-7. PubMed ID: 9250824
[TBL] [Abstract][Full Text] [Related]
14. Expression and secretion of a recombinant ricin immunotoxin from murine myeloma cells.
Krek CE; Ladino CA; Goldmacher VS; Blättler WA; Guild BC
Protein Eng; 1995 May; 8(5):481-9. PubMed ID: 8532670
[TBL] [Abstract][Full Text] [Related]
15. Introduction of a disulfide bond into ricin A chain decreases the cytotoxicity of the ricin holotoxin.
Argent RH; Roberts LM; Wales R; Robertus JD; Lord JM
J Biol Chem; 1994 Oct; 269(43):26705-10. PubMed ID: 7929403
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a ricin fusion toxin targeted to the interleukin-2 receptor.
Frankel AE; Burbage C; Fu T; Tagge E; Chandler J; Willingham M
Protein Eng; 1996 Oct; 9(10):913-9. PubMed ID: 8931131
[TBL] [Abstract][Full Text] [Related]
17. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
Van Horssen PJ; Preijers FW; Van Oosterhout YV; De Witte T
Int J Cancer; 1996 Nov; 68(3):378-83. PubMed ID: 8903481
[TBL] [Abstract][Full Text] [Related]
18. Toxicity, distribution and elimination of the cancerostatic lectins abrin and ricin after parenteral injection into mice.
Fodstad O; Olsnes S; Pihl A
Br J Cancer; 1976 Oct; 34(4):418-25. PubMed ID: 974006
[TBL] [Abstract][Full Text] [Related]
19. [Chimeric toxin of the A-subunit of viscumin and the B-subunit of ricin].
Tonevitskiĭ AG; Toptygin AIu; Agapov II; Shamshiev AT; Pfuller U; Ershova GV; Prokof'ev SA; Rakhmanova VA
Mol Biol (Mosk); 1994; 28(3):574-9. PubMed ID: 7519722
[TBL] [Abstract][Full Text] [Related]
20. Ricin fusion toxin targeted to the human granulocyte-macrophage colony stimulating factor receptor is selectively toxic to acute myeloid leukemia cells.
Burbage C; Tagge EP; Harris B; Hall P; Fu T; Willingham MC; Frankel AE
Leuk Res; 1997 Jul; 21(7):681-90. PubMed ID: 9301690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
